Ingenol mebutate: a novel topical agent for actinic keratosis

Abstract

Ingenol mebutate is a once‐daily topical treatment for actinic keratosis (AK) that is applied for only two or three days depending on body site. It has recently been approved by the FDA for the treatment of AK on the face, scalp, trunk and extremities and recommended for approval by the CHMP in September 2012. In this drug profile, the author reviews its mode of action, efficacy and tolerability and comments on the drug's likely place in practice. Copyright © 2013 John Wiley & Sons, Ltd.